Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 315939, 8 pages
http://dx.doi.org/10.1155/2011/315939
Review Article

Rationale for Possible Targeting of Histone Deacetylase Signaling in Cancer Diseases with a Special Reference to Pancreatic Cancer

1Service de Chirurgie Digestive Pôle d'Oncologie et Spécialités Médico-Chirurgicales, Hôpital Timone, Assistance Pubique-Hôpitaux de Marseille, Marseille, France
2Faculté de Médecine, Aix Marseille Université, Marseille, France
3CR02-INSERM, UMR911, Marseille, France
4Department of General Surgery, Kantonsspital Liestal, 4800 Zofingen, Switzerland
5INSERM, CNRS UMR 5235, Montpellier, France
6IBMC, Universidade do Porto, 4009-002 Porto, Portugal

Received 10 June 2010; Revised 9 September 2010; Accepted 23 September 2010

Academic Editor: Christian Seiser

Copyright © 2011 Mehdi Ouaïssi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” Ca-A Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007. View at Publisher · View at Google Scholar
  2. I. J. Fidler, “The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited,” Nature Reviews Cancer, vol. 3, no. 6, pp. 453–458, 2003. View at Publisher · View at Google Scholar · View at PubMed
  3. L. Rosenberg, “Pancreatic cancer: a review of emerging therapies,” Drugs, vol. 59, no. 5, pp. 1071–1089, 2000. View at Google Scholar
  4. M.-H. Kuo and C. D. Allis, “Roles of histone acetyltransferases and deacetylases in gene regulation,” BioEssays, vol. 20, no. 8, pp. 615–626, 1998. View at Publisher · View at Google Scholar
  5. J. E. Bolden, M. J. Peart, and R. W. Johnstone, “Anticancer activities of histone deacetylase inhibitors,” Nature Reviews Drug Discovery, vol. 5, no. 9, pp. 769–784, 2006. View at Publisher · View at Google Scholar · View at PubMed
  6. R. A. Frye, “Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins,” Biochemical and Biophysical Research Communications, vol. 273, no. 2, pp. 793–798, 2000. View at Publisher · View at Google Scholar · View at PubMed
  7. F. De Nigris, J. Cerutti, C. Morelli et al., “Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues,” British Journal of Cancer, vol. 86, no. 6, pp. 917–923, 2002. View at Publisher · View at Google Scholar · View at PubMed
  8. A. J. M. De Ruijter, A. H. Van Gennip, H. N. Caron, S. Kemp, and A. B. P. Van Kuilenburg, “Histone deacetylases (HDACs): characterization of the classical HDAC family,” Biochemical Journal, vol. 370, no. 3, pp. 737–749, 2003. View at Publisher · View at Google Scholar · View at PubMed
  9. J. E. Bradner, N. West, M. L. Grachan et al., “Chemical phylogenetics of histone deacetylases,” Nature Chemical Biology, vol. 6, no. 3, pp. 238–243, 2010. View at Publisher · View at Google Scholar · View at PubMed
  10. C. M. Grozinger, E. D. Chao, H. E. Blackwell, D. Moazed, and S. L. Schreiber, “Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening,” Journal of Biological Chemistry, vol. 276, no. 42, pp. 38837–38843, 2001. View at Publisher · View at Google Scholar · View at PubMed
  11. A. Bedalov, T. Gatbonton, W. P. Irvine, D. E. Gottschling, and J. A. Simon, “Identification of a small molecule inhibitor of Sir2p,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 26, pp. 15113–15118, 2001. View at Publisher · View at Google Scholar · View at PubMed
  12. J.-H. Choi, H. J. Kwon, B.-I. Yoon et al., “Expression profile of histone deacetylase 1 in gastric cancer tissues,” Japanese Journal of Cancer Research, vol. 92, no. 12, pp. 1300–1304, 2001. View at Google Scholar
  13. P. Zhu, E. Martin, J. Mengwasser, P. Schlag, K.-P. Janssen, and M. Göttlicher, “Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis,” Cancer Cell, vol. 5, no. 5, pp. 455–463, 2004. View at Publisher · View at Google Scholar
  14. A. J. Wilson, D.-S. Byun, N. Popova et al., “Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer,” Journal of Biological Chemistry, vol. 281, no. 19, pp. 13548–13558, 2006. View at Publisher · View at Google Scholar · View at PubMed
  15. M. J. Scanlan, S. Welt, C. M. Gordon et al., “Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets,” Cancer Research, vol. 62, no. 14, pp. 4041–4047, 2002. View at Google Scholar
  16. F. De Nigris, J. Cerutti, C. Morelli et al., “Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues,” British Journal of Cancer, vol. 86, no. 6, pp. 917–923, 2002. View at Publisher · View at Google Scholar · View at PubMed
  17. M. Hiratsuka, T. Inoue, T. Toda et al., “Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene,” Biochemical and Biophysical Research Communications, vol. 309, no. 3, pp. 558–566, 2003. View at Publisher · View at Google Scholar
  18. D. W. Kim, M. A. Sovak, G. Zanieski et al., “Activation of NF-κB/Rel occurs early during neoplastic transformation of mammary cells,” Carcinogenesis, vol. 21, no. 5, pp. 871–879, 2000. View at Google Scholar
  19. W. Weichert, M. Boehm, V. Gekeler et al., “High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis,” British Journal of Cancer, vol. 97, no. 4, pp. 523–530, 2007. View at Publisher · View at Google Scholar · View at PubMed
  20. N. Mori, M. Fujii, S. Ikeda et al., “Constitutive activation of NF-κB in primary adult T-cell leukemia cells,” Blood, vol. 93, no. 7, pp. 2360–2368, 1999. View at Google Scholar
  21. P. C. Cogswell, D. C. Guttridge, W. K. Funkhouser, and A. S. Baldwin Jr., “Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3,” Oncogene, vol. 19, no. 9, pp. 1123–1131, 2000. View at Google Scholar
  22. B. P. Ashburner, S. D. Westerheide, and A. S. Baldwin Jr., “The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression,” Molecular and Cellular Biology, vol. 21, no. 20, pp. 7065–7077, 2001. View at Publisher · View at Google Scholar · View at PubMed
  23. L.-F. Chen, W. Fischle, E. Verdin, and W. C. Greene, “Duration of nuclear NF-κB action regulated by reversible acetylation,” Science, vol. 293, no. 5535, pp. 1653–1657, 2001. View at Publisher · View at Google Scholar · View at PubMed
  24. F. Yeung, J. E. Hoberg, C. S. Ramsey et al., “Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase,” EMBO Journal, vol. 23, no. 12, pp. 2369–2380, 2004. View at Publisher · View at Google Scholar · View at PubMed
  25. M. Yoshida, M. Kijima, M. Akita, and T. Beppu, “Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A,” Journal of Biological Chemistry, vol. 265, no. 28, pp. 17174–17179, 1990. View at Google Scholar
  26. M. S. Finnin, J. R. Donigian, A. Cohen et al., “Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors,” Nature, vol. 401, no. 6749, pp. 188–193, 1999. View at Publisher · View at Google Scholar · View at PubMed
  27. J. E. Bolden, M. J. Peart, and R. W. Johnstone, “Anticancer activities of histone deacetylase inhibitors,” Nature Reviews Drug Discovery, vol. 5, no. 9, pp. 769–784, 2006. View at Publisher · View at Google Scholar · View at PubMed
  28. W. Xu, L. Ngo, G. Perez, M. Dokmanovic, and P. A. Marks, “Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 42, pp. 15540–15545, 2006. View at Publisher · View at Google Scholar · View at PubMed
  29. A. Nebbioso, N. Clarke, E. Voltz et al., “Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells,” Nature Medicine, vol. 11, no. 1, pp. 77–84, 2005. View at Publisher · View at Google Scholar · View at PubMed
  30. A. Insinga, S. Monestiroli, S. Ronzoni et al., “Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway,” Nature Medicine, vol. 11, no. 1, pp. 71–76, 2005. View at Publisher · View at Google Scholar · View at PubMed
  31. A. A. Ruefli, M. J. Ausserlechner, D. Bernhard et al., “The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10833–10838, 2001. View at Publisher · View at Google Scholar · View at PubMed
  32. M. J. Peart, K. M. Tainton, A. A. Ruefli et al., “Novel mechanisms of apoptosis induced by histone deacetylase inhibitors,” Cancer Research, vol. 63, no. 15, pp. 4460–4471, 2003. View at Google Scholar
  33. C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan et al., “Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 2, pp. 540–545, 2004. View at Publisher · View at Google Scholar · View at PubMed
  34. Y. Zhao, J. Tan, L. Zhuang, X. Jiang, E. T. Liu, and Q. Yu, “Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 44, pp. 16090–16095, 2005. View at Publisher · View at Google Scholar · View at PubMed
  35. Y. Zhang, M. Adachi, R. Kawamura, and K. Imai, “Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis,” Cell Death and Differentiation, vol. 13, no. 1, pp. 129–140, 2006. View at Publisher · View at Google Scholar · View at PubMed
  36. R. R. Rosato, J. A. Almenara, and S. Grant, “The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1,” Cancer Research, vol. 63, no. 13, pp. 3637–3645, 2003. View at Google Scholar
  37. P. García-Morales, A. Gómez-Martínez, A. Carrato et al., “Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines,” Molecular Cancer Therapeutics, vol. 4, no. 8, pp. 1222–1230, 2005. View at Publisher · View at Google Scholar · View at PubMed
  38. M. S. Kim, H. J. Kwon, Y. M. Lee et al., “Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes,” Nature Medicine, vol. 7, no. 4, pp. 437–443, 2001. View at Publisher · View at Google Scholar · View at PubMed
  39. D. Z. Qian, Y. Kato, S. Shabbeer et al., “Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589,” Clinical Cancer Research, vol. 12, no. 2, pp. 634–642, 2006. View at Publisher · View at Google Scholar · View at PubMed
  40. T. Maeda, M. Towatari, H. Kosugi, and H. Saito, “Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells,” Blood, vol. 96, no. 12, pp. 3847–3856, 2000. View at Google Scholar
  41. W. J. Magner, A. L. Kazim, C. Stewart et al., “Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors,” Journal of Immunology, vol. 165, no. 12, pp. 7017–7024, 2000. View at Google Scholar
  42. S. Zhao, K. Venkatasubbarao, S. Li, and J. W. Freeman, “Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor β type II receptor expression in human pancreatic cancer cells,” Cancer Research, vol. 63, no. 10, pp. 2624–2630, 2003. View at Google Scholar
  43. P. Reddy, Y. Maeda, K. Hotary et al., “Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 11, pp. 3921–3926, 2004. View at Publisher · View at Google Scholar · View at PubMed
  44. I. Nusinzon and C. M. Horvath, “Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 14742–14747, 2003. View at Publisher · View at Google Scholar · View at PubMed
  45. Z.-L. Yuan, Y.-J. Guan, D. Chatterjee, and Y. E. Chin, “Stat3 dimerization regulated by reversible acetylation of a single lysine residue,” Science, vol. 307, no. 5707, pp. 269–273, 2005. View at Publisher · View at Google Scholar · View at PubMed
  46. A. Moldenhauer, R. C. Frank, J. Pinilla-Ibarz et al., “Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins,” Journal of Leukocyte Biology, vol. 76, no. 3, pp. 623–633, 2004. View at Publisher · View at Google Scholar · View at PubMed
  47. C. Yu, M. Rahmani, D. Conrad, M. Subler, P. Dent, and S. Grant, “The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571,” Blood, vol. 102, no. 10, pp. 3765–3774, 2003. View at Publisher · View at Google Scholar · View at PubMed
  48. S. T. Nawrocki, J. S. Carew, M. S. Pino et al., “Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells,” Cancer Research, vol. 66, no. 7, pp. 3773–3781, 2006. View at Publisher · View at Google Scholar · View at PubMed
  49. S. C. Maggio, R. R. Rosato, L. B. Kramer et al., “The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells,” Cancer Research, vol. 64, no. 7, pp. 2590–2600, 2004. View at Publisher · View at Google Scholar
  50. A. Jemal, T. Murray, E. Ward et al., “Cancer statistics, 2005,” Ca-A Cancer Journal for Clinicians, vol. 55, no. 1, pp. 10–30, 2005. View at Google Scholar
  51. H. A. Burris III, M. J. Moore, J. Andersen et al., “Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial,” Journal of Clinical Oncology, vol. 15, no. 6, pp. 2403–2413, 1997. View at Google Scholar
  52. M. J. Moore, D. Goldstein, J. Hamm et al., “Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1960–1966, 2007. View at Publisher · View at Google Scholar · View at PubMed
  53. H. L. Kindler, D. Niedzwiecki, D. Hollis et al., “A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB),” Journal of Clinical Oncology, vol. 25, no. 18S, article 4508, 2007. View at Google Scholar
  54. P. A. Philip, J. Benedetti, C. Fenoglio-Preiser et al., “Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study,” Journal of Clinical Oncology, vol. 25, article LBA4509, 2007. View at Google Scholar
  55. E. K. Rowinsky, J. J. Windle, and D. D. Von Hoff, “Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development,” Journal of Clinical Oncology, vol. 17, no. 11, pp. 3631–3652, 1999. View at Google Scholar
  56. E. Van Cutsem, H. Van De Velde, P. Karasek et al., “Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer,” Journal of Clinical Oncology, vol. 22, no. 8, pp. 1430–1438, 2004. View at Publisher · View at Google Scholar · View at PubMed
  57. J. Bai, J. Sui, A. Demirjian, C. M. Vollmer Jr., W. Marasco, and M. P. Callery, “Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro,” Cancer Research, vol. 65, no. 6, pp. 2344–2352, 2005. View at Publisher · View at Google Scholar · View at PubMed
  58. N. Bardeesy and R. A. DePinho, “Pancreatic cancer biology and genetics,” Nature Reviews Cancer, vol. 2, no. 12, pp. 897–909, 2002. View at Publisher · View at Google Scholar · View at PubMed
  59. M. Cascalló, J. Calbó, G. Capellà, C. Filiat, M. Pastor-Anglada, and A. Mazo, “Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors,” Oncology, vol. 68, no. 2-3, pp. 179–189, 2005. View at Publisher · View at Google Scholar · View at PubMed
  60. P. García-Morales, A. Gómez-Martínez, A. Carrato et al., “Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines,” Molecular Cancer Therapeutics, vol. 4, no. 8, pp. 1222–1230, 2005. View at Publisher · View at Google Scholar · View at PubMed
  61. M. Donadelli, C. Costanzo, S. Beghelli et al., “Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine,” Biochimica et Biophysica Acta, vol. 1773, no. 7, pp. 1095–1106, 2007. View at Publisher · View at Google Scholar · View at PubMed
  62. J. Bai, A. Demirjian, J. Sui, W. Marasco, and M. P. Callery, “Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells,” Biochemical and Biophysical Research Communications, vol. 348, no. 4, pp. 1245–1253, 2006. View at Publisher · View at Google Scholar · View at PubMed
  63. M. Ouaïssi, S. Cabral, J. Tavares et al., “Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors,” Cancer Biology and Therapy, vol. 7, no. 4, pp. 523–531, 2008. View at Google Scholar
  64. M. Ouaïssi, I. Sielezneff, R. Silvestre et al., “High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas,” Annals of Surgical Oncology, vol. 15, no. 8, pp. 2318–2328, 2008. View at Publisher · View at Google Scholar · View at PubMed
  65. B. Gerdes, A. Ramaswamy, A. Ziegler et al., “p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb,” Annals of Surgery, vol. 235, no. 1, pp. 51–59, 2002. View at Publisher · View at Google Scholar
  66. D. Mottet, A. Bellahcène, S. Pirotte et al., “Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis,” Circulation Research, vol. 101, no. 12, pp. 1237–1246, 2007. View at Publisher · View at Google Scholar · View at PubMed
  67. P. A. Marks and R. Breslow, “Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug,” Nature Biotechnology, vol. 25, no. 1, pp. 84–90, 2007. View at Publisher · View at Google Scholar · View at PubMed
  68. M. Dokmanovic, G. Perez, W. Xu et al., “Histone deacetylase inhibitors selectively suppress expression of HDAC7,” Molecular Cancer Therapeutics, vol. 6, no. 9, pp. 2525–2534, 2007. View at Publisher · View at Google Scholar · View at PubMed
  69. L. Stimson and N. B. La Thangue, “Biomarkers for predicting clinical responses to HDAC inhibitors,” Cancer Letters, vol. 280, no. 2, pp. 177–183, 2009. View at Publisher · View at Google Scholar · View at PubMed
  70. A. Manuyakorn, R. Paulus, J. Farrell et al., “Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704,” Journal of Clinical Oncology, vol. 28, no. 8, pp. 1358–1365, 2010. View at Publisher · View at Google Scholar · View at PubMed
  71. F. Dequiedt, H. Kasler, W. Fischle et al., “HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis,” Immunity, vol. 18, no. 5, pp. 687–698, 2003. View at Publisher · View at Google Scholar
  72. J. Chen, W. Fiskus, K. Eaton et al., “Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism,” Blood, vol. 113, no. 17, pp. 4038–4048, 2009. View at Publisher · View at Google Scholar · View at PubMed
  73. H.-Y. Kao, A. Verdel, C.-C. Tsai, C. Simon, H. Juguilon, and S. Khochbin, “Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7,” Journal of Biological Chemistry, vol. 276, no. 50, pp. 47496–47507, 2001. View at Publisher · View at Google Scholar · View at PubMed
  74. W. Fischle, F. Dequiedt, M. Fillion, M. J. Hendzel, W. Voelter, and E. Verdin, “Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo,” Journal of Biological Chemistry, vol. 276, no. 38, pp. 35826–35835, 2001. View at Publisher · View at Google Scholar · View at PubMed
  75. S. B. Baylin and J. E. Ohm, “Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction?” Nature Reviews Cancer, vol. 6, no. 2, pp. 107–116, 2006. View at Publisher · View at Google Scholar · View at PubMed
  76. P. P. Pandolfi, “Histone deacetylases and transcriptional therapy with their inhibitors,” Cancer Chemotherapy and Pharmacology, vol. 48, no. 1, pp. S17–S19, 2001. View at Publisher · View at Google Scholar